Cover Image
市場調查報告書

ChironWells GmbH的產品平台分析

ChironWells GmbH - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 319969
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
ChironWells GmbH的產品平台分析 ChironWells GmbH - Product Pipeline Review - 2015
出版日期: 2015年12月16日 內容資訊: 英文 24 Pages
簡介

ChironWells GmbH是總公司設置於奧地利的製藥企業,正在開發、銷售疼痛管理,免疫疾病,腸胃障礙的治療藥。開發中產品有HS731,HS378,HS198,其中HS731是對末梢神經作用的類鴉片物質系止痛藥,用於治療中度到重度的急性·慢性疼痛。HS378Calcineurin抑制劑,被用於治療乾癬,異位性皮膚炎,類風濕性關節炎等免疫性疾病。

本報告提供ChironWells GmbH的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,加上最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

ChironWells GmbH的基本資料

  • ChironWells GmbH概要
  • 主要資訊
  • 企業資料

ChironWells GmbH:R&D概要

  • 主要的治療範圍

ChironWells GmbH:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

ChironWells GmbH:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

ChironWells GmbH:藥物簡介

  • HS-198
  • HS-378
  • HS-731
  • Small Molecule for Bowel Motility Disorders
  • Small Molecule to Agonize OP3 Receptor for Inflammatory Bowel Diseases

ChironWells GmbH:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

ChironWells GmbH:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07869CDB

Summary

Global Markets Direct's, 'ChironWells GmbH - Product Pipeline Review - 2015', provides an overview of the ChironWells GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ChironWells GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of ChironWells GmbH including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of ChironWells GmbH's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the ChironWells GmbH's pipeline products

Reasons to buy

  • Evaluate ChironWells GmbH's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of ChironWells GmbH in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the ChironWells GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of ChironWells GmbH and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of ChironWells GmbH
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of ChironWells GmbH and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ChironWells GmbH Snapshot
    • ChironWells GmbH Overview
    • Key Information
    • Key Facts
  • ChironWells GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • ChironWells GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • ChironWells GmbH - Pipeline Products Glance
    • ChironWells GmbH - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • ChironWells GmbH - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • ChironWells GmbH - Drug Profiles
    • HS-731
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HS-198
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HS-378
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize OP3 Receptor for Crohn's Disease and Ulcerative Colitis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize OP3 Receptor for Bowel Motility Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • ChironWells GmbH - Pipeline Analysis
  • ChironWells GmbH - Pipeline Products by Target
  • ChironWells GmbH - Pipeline Products by Route of Administration
  • ChironWells GmbH - Pipeline Products by Molecule Type
  • ChironWells GmbH - Pipeline Products by Mechanism of Action
  • ChironWells GmbH - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ChironWells GmbH, Key Information
  • ChironWells GmbH, Key Facts
  • ChironWells GmbH - Pipeline by Indication, 2015
  • ChironWells GmbH - Pipeline by Stage of Development, 2015
  • ChironWells GmbH - Monotherapy Products in Pipeline, 2015
  • ChironWells GmbH - Phase I, 2015
  • ChironWells GmbH - Preclinical, 2015
  • ChironWells GmbH - Discovery, 2015
  • ChironWells GmbH - Pipeline by Target, 2015
  • ChironWells GmbH - Pipeline by Route of Administration, 2015
  • ChironWells GmbH - Pipeline by Molecule Type, 2015
  • ChironWells GmbH - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • ChironWells GmbH - Pipeline by Top 10 Indication, 2015
  • ChironWells GmbH - Pipeline by Stage of Development, 2015
  • ChironWells GmbH - Monotherapy Products in Pipeline, 2015
  • ChironWells GmbH - Pipeline by Top 10 Target, 2015
  • ChironWells GmbH - Pipeline by Top 10 Route of Administration, 2015
  • ChironWells GmbH - Pipeline by Top 10 Molecule Type, 2015
  • ChironWells GmbH - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top